Skip to main content

Table 3 Discrimination and reclassification improvements of mtDNA 8-OHdG beyond the 2013 ACC/AHA PCE and the FRS in 1920 patients with T2DM

From: Mitochondrial 8-hydroxy-2′-deoxyguanosine and coronary artery disease in patients with type 2 diabetes mellitus

Risk estimatesACC/AHA 2013 PCE + mtDNA 8-OHdGFRS + mtDNA 8-OHdG
< 20%20–50%> 50%TotalReclassified< 20%20–50%> 50%TotalReclassified
Individuals without obstructive CAD, No.
 < 20%2682302918%3521003623%
 20–50%682754138428%591911426428%
 > 50%04814319125%02721324011%
 Total336346184866 411228227866 
Individuals with obstructive CAD, No.
 < 20%12530315821%105701126%
 20–50%352888240529%302054127626%
 > 50%0354564917%0316356665%
 Total1603535411054 1352436761054 
 Estimate (95% CI)P valueEstimate (95% CI)P value
Δ C-statistic0.024 (0.013–0.035)< 0.0010.010 (0.003–0.017)0.003
IDI0.020 (0.014–0.026)< 0.0010.014 (0.001–0.019)< 0.001
NRI continuous0.299 (0.210–0.388)< 0.0010.196 (0.107–0.286)< 0.001
NRI categorical0.103 (0.064–0.142)< 0.0010.059 (0.029–0.090)< 0.001
  1. PCE ACC/AHA Pooled Cohorts Equations, FRS the Framingham Risk Score, IDI integrated discrimination improvement, NRI integrated discrimination improvement